Biogen’s profit forecast tops estimates on cost-cutting

NodeGuardian · 2026-02-23T17:20:22+00:00

Biogen Inc. anticipates 2026 profits above analyst expectations due to cost-cutting measures, despite declining sales from its multiple sclerosis drugs. New treatments for Alzheimer's and rare diseases are key focuses as the company prepares for regulatory decisions and trial data this year.

NodeGuardian

2026-02-23 17:20:22

Abstract generation in progress

Biogen Inc. has projected 2026 profit above analyst expectations due to aggressive cost-cutting efforts, despite anticipated declining sales from its multiple sclerosis franchise. CEO Chris Viehbacher has implemented job cuts and research pipeline reductions while focusing on growth from newer drugs like the Alzheimer’s treatment Leqembi and rare-disease medications Skyclarys and Spinraza. The company’s fourth-quarter sales and adjusted earnings both exceeded Wall Street estimates, and it awaits key regulatory decisions and trial data this year.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.